Incyte Corporation (NASDAQ:INCY) — Market Cap & Net Worth
Market Cap & Net Worth: Incyte Corporation (INCY)
Incyte Corporation (NASDAQ:INCY) has a market capitalization of $24.43 Billion ($24.43 Billion) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #1091 globally and #456 in its home market, demonstrating a 0.28% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Incyte Corporation's stock price $124.75 by its total outstanding shares 202697746 (202.70 Million). Also see INCY asset base for a full breakdown of the balance sheet.
Incyte Corporation Market Cap History: 2015 to 2026
Incyte Corporation's market capitalization history from 2015 to 2026. Data shows growth from $21.98 Billion to $25.29 Billion (1.10% CAGR). Also see how efficiently does Incyte Corporation generate cash for how efficiently the company converts equity into cash flow.
Index Memberships
Incyte Corporation is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$1.06 Trillion | 2.31% | #12 of 30 |
|
Dow Jones Biotechnology
DJUSBT
|
$1.16 Trillion | 2.11% | #8 of 39 |
|
S&P 500 Index
GSPC
|
$62.72 Trillion | 0.02% | #326 of 503 |
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.92% | #19 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.06% | #134 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 1.30% | #13 of 263 |
Weight: Incyte Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Incyte Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Incyte Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Incyte Corporation (INCY) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
3.89x
Incyte Corporation's market cap is 3.89 times its annual revenue
Latest Price to Earnings (P/E) Ratio
15.56x
Incyte Corporation's market cap is 15.56 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $20.32 Billion | $1.11 Billion | $104.22 Million | 18.38x | 195.01x |
| 2017 | $19.20 Billion | $1.54 Billion | -$313.14 Million | 12.50x | N/A |
| 2018 | $12.89 Billion | $1.88 Billion | $109.49 Million | 6.85x | 117.72x |
| 2019 | $17.70 Billion | $2.16 Billion | $446.91 Million | 8.20x | 39.60x |
| 2020 | $17.63 Billion | $2.67 Billion | -$295.70 Million | 6.61x | N/A |
| 2021 | $14.88 Billion | $2.99 Billion | $948.58 Million | 4.98x | 15.68x |
| 2022 | $16.28 Billion | $3.39 Billion | $340.66 Million | 4.80x | 47.79x |
| 2023 | $12.73 Billion | $3.70 Billion | $597.60 Million | 3.44x | 21.30x |
| 2024 | $14.00 Billion | $4.24 Billion | $32.62 Million | 3.30x | 429.26x |
| 2025 | $20.02 Billion | $5.14 Billion | $1.29 Billion | 3.89x | 15.56x |
Competitor Companies of INCY by Market Capitalization
Companies near Incyte Corporation in the global market cap rankings as of September 17, 2026. Review INCY tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Incyte Corporation by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Incyte Corporation Historical Marketcap From 2015 to 2026
Between 2015 and today, Incyte Corporation's market cap moved from $21.98 Billion to $ 25.29 Billion, with a yearly change of 1.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $25.29 Billion | +26.30% |
| 2025 | $20.02 Billion | +43.00% |
| 2024 | $14.00 Billion | +10.00% |
| 2023 | $12.73 Billion | -21.83% |
| 2022 | $16.28 Billion | +9.43% |
| 2021 | $14.88 Billion | -15.61% |
| 2020 | $17.63 Billion | -0.39% |
| 2019 | $17.70 Billion | +37.32% |
| 2018 | $12.89 Billion | -32.86% |
| 2017 | $19.20 Billion | -5.55% |
| 2016 | $20.32 Billion | -7.54% |
| 2015 | $21.98 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Incyte Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $24.43 Billion USD |
| MoneyControl | $24.43 Billion USD |
| MarketWatch | $24.43 Billion USD |
| marketcap.company | $24.43 Billion USD |
| Reuters | $24.43 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chr… Read more